Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in advanced hepatocellular carcinoma
NCT02421185Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of erdafitinib in hepatocellular carcinoma (HCC), sponsored by Janssen Pharmaceutical. Started May 2015; status: completed.
02
Drugs
erdafitinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02421185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421185.